Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Monte Rosa Therapeutics ( (GLUE) ) is now available.
On January 7, 2026, Monte Rosa Therapeutics reported positive interim results from a Phase 1 trial of its NEK7-directed molecular glue degrader MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease (CVD) risk, showing rapid, deep and sustained NEK7 degradation of around 80–90% across single and multiple ascending dose cohorts and in a Part 3 cohort. As of the December 23, 2025 data cutoff, four weeks of MRT-8102 treatment in 24 high‑risk CVD subjects reduced high-sensitivity C-reactive protein (hsCRP) by 85%, with 94% of participants achieving hsCRP levels below 2 mg/L, alongside marked suppression of IL‑1β and IL‑6, including a 55% median IL‑6 reduction in high‑CRP subjects and notable cerebrospinal fluid IL‑6 decreases in two participants, while maintaining a favorable safety profile with only mild to moderate, self-resolving adverse events and no signal of increased infection risk; the strength of these inflammation and biomarker data underpins Monte Rosa’s plans to advance MRT‑8102 into broader development for atherosclerotic cardiovascular disease and other NLRP3/IL‑1/IL‑6‑driven inflammatory conditions, and supports its broader molecular glue degrader pipeline in both immunology and oncology.
The most recent analyst rating on (GLUE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.
Spark’s Take on GLUE Stock
According to Spark, TipRanks’ AI Analyst, GLUE is a Outperform.
The score is driven primarily by materially improved financial performance (profitability and standout free cash flow) and reinforced by positive clinical and partnership events. Offsetting factors are a neutral-to-mixed technical setup and a high P/E valuation that increases sensitivity to any execution or durability setbacks.
To see Spark’s full report on GLUE stock, click here.
More about Monte Rosa Therapeutics
Monte Rosa Therapeutics is a Boston-based, clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines, small-molecule protein degraders designed to address serious diseases that are driven by targets not readily addressed by other therapeutic modalities, with active programs in inflammatory, cardiovascular and oncology indications.
Average Trading Volume: 1,137,585
Technical Sentiment Signal: Buy
Current Market Cap: $937.7M
Learn more about GLUE stock on TipRanks’ Stock Analysis page.